# Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection

> **NCT00125099** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 21 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** VRC-HIVDNA009-00-VP

## Key facts

- **NCT ID:** NCT00125099
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2021-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00125099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00125099, "Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00125099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*